Insight that moves business

GST overhaul cuts tax on medicines & devices, making healthcare affordable. Pharma and medtech must realign pricing, supply chains, and innovation to drive access and growth.

Discover how Delhi’s healthcare system is evolving, insights from Grant Thornton Bharat on infrastructure gaps, investment needs, and policy focus.

The report captures sector-wise shifts, investor alignment with scalable and tech-integrated models, and emerging preferences in early-stage innovation.

The first quarter of 2025 reflected sustained investor attention in India’s healthcare and pharmaceutical sector, marked by consistent deal activity and strategic alignment with long-term growth drivers.

India's healthcare sector is at a crucial juncture, driven by rising demand, increasing investments, and evolving financial models.

Unlike many other diseases, cancer care is uniquely complex, involving prolonged treatment regimens, high costs, and significant emotional distress for patients and their families.

Get insights on Q3 2024 pharma and healthcare deals covers record-high domestic deals, PE trends, and capital market activity reshaping India's healthcare industry.

Discover Grant Thornton Bharat's insights into the inclusive budget's role in fostering a healthier and vibrant India. Learn about key policies on society.

As India anticipates its new budget announcement, there is a heightened sense of expectation, especially within the Government & Public Services (G&PS) sector.

Q2 2024 sees a advancement in Indian healthcare & pharma deals. Seen increased investments in API, biotechnology, and CDMO segments. Explore insights now.

Our latest report, “Impact of climate change on human health: Decoding the risks,” highlights the urgent need for intersectoral collaboration across environment, health, energy, transport, and food sectors.